• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Valle, Juan W
    Faivre, S
    Hubner, Richard A
    Grande, E
    Raymond, E
    Affiliation
    University of Manchester, Manchester Health Sciences Centre and Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
    Issue Date
    2014-09-16
    
    Metadata
    Show full item record
    Abstract
    Pancreatic neuroendocrine tumors (pNETs) are infrequent malignancies which manifest in both functional (hormone-secreting) and more commonly non-functional (non-secreting) forms. The oral multitargeted tyrosine kinase inhibitor sunitinib and mammalian target of rapamycin (mTOR) inhibitor everolimus are approved as targeted therapies for patients with well-differentiated, non-resectable disease and evidence of disease progression. The recent approval of sunitinib for the management of advanced pNET is based on a continuous daily dosing (CDD) schedule that differs from the intermittent 4weeks on/2weeks off (4/2) schedule approved for sunitinib in advanced renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Therefore, although clinicians may be familiar with therapy management approaches for sunitinib in advanced RCC and GIST, there is less available experience for the management of patients with a CDD schedule. Here, we discuss the similarities and differences in the treatment of pNET with sunitinib compared with advanced RCC and GIST. In particular, we focus on the occurrence and management of sunitinib-related toxicity in patients with pNET by drawing on experience in these other malignancies. We aim to provide a relevant and useful guide for clinicians treating patients with pNET covering the management of events such as fatigue, mucositis, hand-foot syndrome, and hypertension.
    Citation
    Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. 2014: Cancer Treat Rev
    Journal
    Cancer Treatment Reviews
    URI
    http://hdl.handle.net/10541/333870
    DOI
    10.1016/j.ctrv.2014.09.001
    PubMed ID
    25283354
    Type
    Article
    Language
    en
    ISSN
    1532-1967
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ctrv.2014.09.001
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Sunitinib and everolimus in pancreatic neuroendocrine tumors.
    • Authors: Procopio G, Pusceddu S, Buzzoni R
    • Issue date: 2012 May-Jun
    • Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    • Authors: Papaetis GS, Syrigos KN
    • Issue date: 2009
    • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    • Authors: Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P
    • Issue date: 2011 Feb 10
    • Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.
    • Authors: Vázquez S, León L, Fernández O, Lázaro M, Grande E, Aparicio L
    • Issue date: 2012 Mar
    • Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    • Authors: Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK
    • Issue date: 2009 Nov
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.